|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar
|
|
3
|
Boyle GM: Therapy for metastatic melanoma:
An overview and update. Expert Rev Anticancer Ther. 11:725–737.
2011. View Article : Google Scholar
|
|
4
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
5
|
Miller AJ and Mihm MC Jr: Melanoma. N Engl
J Med. 355:51–65. 2006. View Article : Google Scholar
|
|
6
|
Mirzaei H, Gholamin S, Shahidsales S,
Sahebkar A, Jaafari MR, Mirzaei HR, Hassanian SM and Avan A:
MicroRNAs as potential diagnostic and prognostic biomarkers in
melanoma. Eur J Cancer. 53:25–32. 2016. View Article : Google Scholar
|
|
7
|
Eggermont AM and Kirkwood JM:
Re-evaluating the role of dacarbazine in metastatic melanoma: What
have we learned in 30 years? Eur J Cancer. 40:1825–1836. 2004.
View Article : Google Scholar
|
|
8
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar
|
|
9
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar
|
|
10
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar
|
|
11
|
Caramel J, Papadogeorgakis E, Hill L,
Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J,
Hutchinson P, Tse G, et al: A switch in the expression of embryonic
EMT-inducers drives the development of malignant melanoma. Cancer
Cell. 24:466–480. 2013. View Article : Google Scholar
|
|
12
|
Denecker G, Vandamme N, Akay O, Koludrovic
D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M,
Brochez L, et al: Identification of a ZEB2-MITF-ZEB1
transcriptional network that controls melanogenesis and melanoma
progression. Cell Death Differ. 21:1250–1261. 2014. View Article : Google Scholar
|
|
13
|
Blomquist P, Belikov S and Wrange O:
Increased nuclear factor 1 binding to its nucleosomal site mediated
by sequence-dependent DNA structure. Nucleic Acids Res. 27:517–525.
1999. View Article : Google Scholar
|
|
14
|
Gronostajski RM: Roles of the NFI/CTF gene
family in transcription and development. Gene. 249:31–45. 2000.
View Article : Google Scholar
|
|
15
|
Chaudhry AZ, Lyons GE and Gronostajski RM:
Expression patterns of the four nuclear factor I genes during mouse
embryogenesis indicate a potential role in development. Dev Dyn.
208:313–325. 1997. View Article : Google Scholar
|
|
16
|
Li S and Rosen JM: Nuclear factor I and
mammary gland factor (STAT5) play a critical role in regulating rat
whey acidic protein gene expression in transgenic mice. Mol Cell
Biol. 15:2063–2070. 1995. View Article : Google Scholar
|
|
17
|
Kane R, Finlay D, Lamb T and Martin F:
Transcription factor NF 1 expression in involuting mammary gland.
Adv Exp Med Biol. 480:117–122. 2000. View Article : Google Scholar
|
|
18
|
Chen KS, Lim JWC, Richards LJ and Bunt J:
The convergent roles of the nuclear factor I transcription factors
in development and cancer. Cancer Lett. 410:124–138. 2017.
View Article : Google Scholar
|
|
19
|
Stringer BW, Bunt J, Day BW, Barry G,
Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S,
et al: Nuclear factor one B (NFIB) encodes a subtype-specific
tumour suppressor in glioblastoma. Oncotarget. 7:29306–29320. 2016.
View Article : Google Scholar
|
|
20
|
Moon HG, Hwang KT, Kim JA, Kim HS, Lee MJ,
Jung EM, Ko E, Han W and Noh DY: NFIB is a potential target for
estrogen receptor-negative breast cancers. Mol Oncol. 5:538–544.
2011. View Article : Google Scholar
|
|
21
|
Xing D, Bakhsh S, Melnyk N, Isacson C, Ho
J, Huntsman DG, Gilks CB, Ronnett BM and Horlings HM: Frequent
NFIB-associated gene rearrangement in adenoid cystic carcinoma of
the vulva. Int J Gynecol Pathol. 36:289–293. 2017. View Article : Google Scholar
|
|
22
|
Liu Z, Chen J, Yuan W, Ruan H, Shu Y, Ji
J, Wu L, Tang Q, Zhou Z, Zhang X, et al: Nuclear factor I/B
promotes colorectal cancer cell proliferation,
epithelial-mesenchymal transition and 5-fluorouracil resistance.
Cancer Sci. 110:86–98. 2019. View Article : Google Scholar
|
|
23
|
Fane ME, Chhabra Y, Hollingsworth DEJ,
Simmons JL, Spoerri L, Oh TG, Chauhan J, Chin T, Harris L, Harvey
TJ, et al: NFIB Mediates BRN2 driven melanoma cell migration and
invasion through regulation of EZH2 and MITF. Ebiomedicine.
16:63–75. 2017. View Article : Google Scholar
|
|
24
|
Hebert SL, Simmons C, Thompson AL, Zorc
CS, Blalock EM and Kraner SD: Basic helix-loop-helix factors
recruit nuclear factor I to enhance expression of the NaV 1.4
Na+ channel gene. Biochim Biophys Acta. 1769:649–658.
2007. View Article : Google Scholar
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar
|
|
27
|
Barry G, Piper M, Lindwall C, Moldrich R,
Mason S, Little E, Sarkar A, Tole S, Gronostajski RM and Richards
LJ: Specific glial populations regulate hippocampal morphogenesis.
J Neurosci. 28:12328–12340. 2008. View Article : Google Scholar
|
|
28
|
Piper M, Barry G, Harvey TJ, McLeay R,
Smith AG, Harris L, Mason S, Stringer BW, Day BW, Wray NR, et al:
NFIB-mediated repression of the epigenetic factor Ezh2 regulates
cortical development. J Neurosci. 34:2921–2930. 2014. View Article : Google Scholar
|
|
29
|
Becker-Santos DD, Lonergan KM,
Gronostajski RM and Lam WL: Nuclear factor I/B: A master regulator
of cell differentiation with paradoxical roles in cancer.
EBioMedicine. 22:2–9. 2017. View Article : Google Scholar
|
|
30
|
Suzuki H, Aoki K, Chiba K, Sato Y,
Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F,
et al: Mutational landscape and clonal architecture in grade II and
III gliomas. Nat Genet. 47:458–468. 2015. View Article : Google Scholar
|
|
31
|
Dooley AL, Winslow MM, Chiang DY, Banerji
S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson
RT, et al: Nuclear factor I/B is an oncogene in small cell lung
cancer. Genes Dev. 25:1470–1475. 2011. View Article : Google Scholar
|
|
32
|
Brayer KJ, Frerich CA, Kang H and Ness SA:
Recurrent fusions in MYB and MYBL1 define a common, transcription
factor-driven oncogenic pathway in salivary gland adenoid cystic
carcinoma. Cancer Discov. 6:176–187. 2016. View Article : Google Scholar
|
|
33
|
Denny SK, Yang D, Chuang CH, Brady JJ, Lim
JS, Grüner BM, Chiou SH, Schep AN, Baral J, Hamard C, et al: Nfib
promotes metastasis through a widespread increase in chromatin
accessibility. Cell. 166:328–342. 2016. View Article : Google Scholar
|
|
34
|
Liu RZ, Vo TM, Jain S, Choi WS, Garcia E,
Monckton EA, Mackey JR and Godbout R: NFIB promotes cell survival
by directly suppressing p21 transcription in TP53-mutated
triple-negative breast cancer. J Pathol. 247:186–198. 2019.
View Article : Google Scholar
|
|
35
|
Lin K, Baritaki S, Militello L, Malaponte
G, Bevelacqua Y and Bonavida B: The role of B-RAF mutations in
melanoma and the induction of EMT via dysregulation of the
NF-ΚB/Snail/RKIP/PTEN circuit. Genes Cancer. 1:409–420. 2010.
View Article : Google Scholar
|
|
36
|
Perrot CY, Javelaud D and Mauviel A:
Insights into the transforming growth factor-beta signaling pathway
in cutaneous melanoma. Ann Dermatol. 25:135–144. 2013. View Article : Google Scholar
|
|
37
|
Wu C, Zhu X, Liu W, Ruan T, Wan W and Tao
K: NFIB promotes cell growth, aggressiveness, metastasis and EMT of
gastric cancer through the Akt/Stat3 signaling pathway. Oncol Rep.
40:1565–1573. 2018.
|
|
38
|
Ren J, Chen Y, Song H, Chen L and Wang R:
Inhibition of ZEB1 reverses EMT and chemoresistance in
docetaxel-resistant human lung adenocarcinoma cell line. J Cell
Biochem. 114:1395–1403. 2013. View Article : Google Scholar
|
|
39
|
Zhang P, Sun Y and Ma L: ZEB1: At the
crossroads of epithelial-mesenchymal transition, metastasis and
therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar
|
|
40
|
Spaderna S, Schmalhofer O, Wahlbuhl M,
Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A,
et al: The transcriptional repressor ZEB1 promotes metastasis and
loss of cell polarity in cancer. Cancer Res. 68:537–544. 2008.
View Article : Google Scholar
|
|
41
|
Gheldof A, Hulpiau P, van Roy F, De Craene
B and Berx G: Evolutionary functional analysis and molecular
regulation of the ZEB transcription factors. Cell Mol Life Sci.
69:2527–2541. 2012. View Article : Google Scholar
|
